IL-17 Receptor - Brodalumab, a Human Anti Psoriatic Skin by Treatment with Gene Expression Profiles Normalized in

The IL-17 pathway is an established driver of psoriasis pathogenesis. We examined the detailed molecular and cellular effects of blockade of IL-17 signaling in human psoriatic skin before and following treatment with brodalumab, a competitive inhibitor of the IL-17 Receptor A subunit. Thousands of aberrantly expressed genes in lesional skin normalized within 2 weeks following brodalumab treatment, with conversion of the lesional psoriasis transcriptome to resemble that seen in nonlesional skin. Keratinocyte-expressed genes appeared to normalize rapidly, whereas T cell–specific normalization occurred over six weeks. The three IL-17 ligand genes that are upregulated in lesional skin, IL17A , IL17C , and IL17F , were all downregulated in a dose-dependent manner following brodalumab treatment. Cellular measures also showed a similar pattern with dramatic decreases in keratinocyte hyperplasia within one week, and decreases in infiltrating leukocytes occurred over a longer timescale. Individuals with the highest brodalumab exposure showed normalization of both IL-17–responsive genes and the psoriasis transcriptome, whereas subjects with lower exposures showed transient or incomplete molecular responses. Clinical and molecular response appeared dependent on the extent of brodalumab exposure relative to the expression of IL-17 ligand genes, and reduction of IL-17 signaling into the nonlesional range was strongly correlated with normalization of the psoriasis transcriptome. These data indicate that blockade of IL-17 signaling in psoriatic skin leads to rapid transcriptomal changes initially in keratinocyte-expressed genes, followed by normalization in the leukocyte abnormalities, and demonstrates the essential role of the IL-17R on keratinocytes in driving disease pathogenesis. The Journal of Immunology

[1]  D. Salinger,et al.  Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies , 2014, Journal of clinical pharmacology.

[2]  David A. Martin,et al.  The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. , 2013, Trends in immunology.

[3]  J. Gudjonsson,et al.  Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation , 2013, The Journal of Immunology.

[4]  Rosa Parisi,et al.  Global epidemiology of psoriasis: a systematic review of incidence and prevalence. , 2013, The Journal of investigative dermatology.

[5]  James T. Elder,et al.  Susceptibility-associated genetic variation at IL12B enhances Th1 polarization in psoriasis. , 2013, Human molecular genetics.

[6]  Hugh A. Rand,et al.  Cross-Study Homogeneity of Psoriasis Gene Expression in Skin across a Large Expression Range , 2013, PloS one.

[7]  Jennifer E Towne,et al.  The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. , 2013, The Journal of investigative dermatology.

[8]  D. Salinger,et al.  Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. , 2012, The Journal of investigative dermatology.

[9]  P. Haslett,et al.  IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. , 2012, The Journal of allergy and clinical immunology.

[10]  J. Ortonne,et al.  Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. , 2012, The New England journal of medicine.

[11]  Subhashis Banerjee,et al.  Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. , 2012, The New England journal of medicine.

[12]  S. Raychaudhuri,et al.  Functional role of IL-22 in psoriatic arthritis , 2012, Arthritis Research & Therapy.

[13]  S. Woo,et al.  IL-17 and IL-22 enhance skin inflammation by stimulating the secretion of IL-1β by keratinocytes via the ROS-NLRP3-caspase-1 pathway. , 2012, International immunology.

[14]  M. Suárez-Fariñas,et al.  A single intradermal injection of IFN-γ induces an inflammatory state in both non-lesional psoriatic and healthy skin , 2011, The Journal of investigative dermatology.

[15]  Z. Modrušan,et al.  IL-17C regulates the innate immune function of epithelial cells in an autocrine manner , 2011, Nature Immunology.

[16]  H. Dinh,et al.  IL-36R ligands are potent regulators of dendritic and T cells. , 2011, Blood.

[17]  S. Gaffen.  Recent advances in the IL-17 cytokine family. , 2011, Current opinion in immunology.

[18]  C. Bodemer,et al.  Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity , 2011, Science.

[19]  S. Chimenti,et al.  Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. , 2011, The Journal of investigative dermatology.

[20]  P. Tak,et al.  Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis , 2010, Science Translational Medicine.

[21]  F. Bernard,et al.  Skin Inflammation Induced by the Synergistic Action of IL-17A, IL-22, Oncostatin M, IL-1α, and TNF-α Recapitulates Some Features of Psoriasis , 2010, The Journal of Immunology.

[22]  Mayte Suárez-Fariñas,et al.  Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. , 2009, The Journal of allergy and clinical immunology.

[23]  Hadley Wickham,et al.  ggplot2 - Elegant Graphics for Data Analysis (2nd Edition) , 2017 .

[24]  B. Thiers.  Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis: Results of a Randomized, Placebo-Controlled, Phase 2 Trial , 2009 .

[25]  Lisa C. Zaba,et al.  Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways , 2008, The British journal of dermatology.

[26]  M. Lebwohl,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) , 2008, The Lancet.

[27]  Lisa C. Zaba,et al.  Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. , 2008, The Journal of investigative dermatology.

[28]  Lisa C. Zaba,et al.  Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses , 2007, The Journal of experimental medicine.

[29]  K. Boyd,et al.  The inhibitory cytokine IL-35 contributes to regulatory T-cell function , 2007, Nature.

[30]  James T. Elder,et al.  Psoriasis: epidemiology. , 2007, Clinics in dermatology.

[31]  Frank O. Nestle,et al.  Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis , 2007, Human Genetics.

[32]  P. Valdez,et al.  Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis , 2007, Nature.

[33]  F. Nestle,et al.  Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha. , 2005, The Journal of investigative dermatology.

[34]  A. Nakanishi,et al.  A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction , 2005, The British journal of dermatology.

[35]  K. Wittkowski,et al.  Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  L. Naldi,et al.  Epidemiology of psoriasis. , 2004, Current drug targets. Inflammation and allergy.

[37]  T P Speed,et al.  Experimental design and low-level analysis of microarray data. , 2004, International review of neurobiology.